Fig. 7: PTPN23 Bro40 suppresses lung cancer progression and overcomes EGFR TKI resistance. | Cell Death & Disease

Fig. 7: PTPN23 Bro40 suppresses lung cancer progression and overcomes EGFR TKI resistance.

From: PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target

Fig. 7: PTPN23 Bro40 suppresses lung cancer progression and overcomes EGFR TKI resistance.

A Volcano plot for the comparison of RNA-seq data derived from H1299 cells expressing GFP-Bro40 and GFP-Bro40mut. DEGs are marked by blue and red dots. B GO analysis of genes that are downregulated by GFP-Bro40 in comparison with GFP-Bro40mut. C–F Cell proliferation, migration, and invasion analyses of H1299 or H1975 cells transiently transfected with GFP-Bro40 or GFP-Bro40mut. Data are represented as individual points and mean, n = 3. P-values are determined by two-sided Student’s t-test, ***P < 0.001. G MTT assay for H1975 cells transiently transfected with GFP-Bro40 or GFP-Bro40mut or treated with 1 µM gefitinib for 48 h. Data are represented as individual points and mean, n = 3. P-values are determined by one-way ANOVA with Tukey’s post hoc test, **P < 0.01. ns: not significant. H Mice that are subcutaneously transplanted with H1975 cells were treated with GFP-Bro40 or GFP-Bro40mut liposome nanoparticle or with gefitinib starting at day 21 after tumor cell implantation (Top panel). Tumor volumes were measured on the indicated days and plotted (bottom left panel). Data are mean ± SD, n = 5. P-values are determined by two-way ANOVA with Tukey’s post-hoc test, ***P < 0.001. Tumors were surgically removed on day 37 and their sizes are shown on the right. I Mice that were intravenously injected with H1975 cells were treated with GFP-Bro40 or GFP-Bro40mut liposome nanoparticle or with gefitinib as illustrated on the top panel. Representative images of bioluminescence analysis at day 56 after tumor cell injection are shown on the bottom left panel and the kinetics of metastasis are shown on the bottom right panel. Data are mean ± SD, n = 5. P-values are determined by two-way ANOVA with Tukey’s post-hoc test, **P < 0.01, ***P < 0.001. J Representative lung images on day 56 of the experiment shown in I. Nodules are indicated by arrows and the number of metastatic nodules at the surface of lungs are shown on the right. Data are represented as individual points and mean, n = 5. P-values are determined by one-way ANOVA with Sidak’s multi-comparison test, ***P < 0.001.

Back to article page